Table 5.
Characteristic of AML patients treatment in validation cohort
| Variable | UBE2E1 high | UBE2E1 low | p |
|---|---|---|---|
| Treatment, no.(%) | 25(100) | 25(100) | 0.422 |
| CAG | 2(8) | 1(4) | |
| DA | 9(36) | 11(44) | |
| QA | 1(4) | 0 | |
| HAD | 1(4) | 0 | |
| IDA | 6(24) | 11(44) | |
| D-CAG | 2(8) | 1(4) | |
| Allo-HSCT | 0(0) | 0(0) |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.